Maegim한국어

엠에프씨

432980KOSDAQSector: Pharma & Biotech
₩2,690▲ 0.56%Market cap ₩23.1BAs of Jul 21, 2026 close · updated once daily
B
Grade B57.8 ptsTop 39% of 2,523 stocks
Financial strength
66.8
Growth momentum
23.6
Price attractiveness
71.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

66.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
18.7%
✓ Above median · Top 21.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
359.0%
✓ Above median · Top 31.9% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
1.4%
✓ Above median · Top 43.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
2.7%
✓ Above median · Top 36% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

23.6
How much did revenue grow in a year?
Revenue growth (YoY)
0.9%
✗ Below median · Top 64.2% in sector
Sector median 6.4%
Did core profits grow in a year?
Operating income change (YoY)
-79.7%
✗ Below median · Top 88.6% in sector
Sector median 3.6%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

71.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
28.1x
✓ Above median · Top 29.5% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.77x
✓ Above median · Top 27% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15